Neuroblastoma patients are stratified into low-, intermediate-, and high-risk groups based on different parameters, including tumor histology, clinical stage, tumor cell ploidy, and MYCN oncogene amplification, which are present in 20–25% of the cases and are correlated with high-risk disease and poor prognosis [99]. Here, MYCN is linked to neuroblastoma.